{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Topical&page=52",
    "query": {
      "intervention": "Topical",
      "page": 52
    },
    "page_size": 10
  },
  "pagination": {
    "page": 52,
    "page_size": 10,
    "total_count": 2652,
    "total_pages": 266,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Topical&page=53&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Topical&page=51&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T03:49:26.054Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05217160",
      "title": "Pilot Study: KeraStat® Gel for Topical Delivery of Morphine for Management of Non-Healing, Painful Open Wounds and Ulcers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Wound of Skin",
        "Burns"
      ],
      "interventions": [
        {
          "name": "KeraStat® Gel with Morphine application",
          "type": "DRUG"
        },
        {
          "name": "KeraStat® Gel application",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Metis Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2021-05-11",
      "completion_date": "2022-05-31",
      "has_results": false,
      "last_update_posted_date": "2022-02-01",
      "last_synced_at": "2026-10-28T03:49:26.054Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05217160"
    },
    {
      "nct_id": "NCT03812510",
      "title": "Safety Study of A-101 Topical Solution for the Treatment of Common Warts",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Common Wart"
      ],
      "interventions": [
        {
          "name": "A-101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aclaris Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Year and older"
      },
      "enrollment_count": 426,
      "start_date": "2019-02-07",
      "completion_date": "2019-12-20",
      "has_results": true,
      "last_update_posted_date": "2020-11-23",
      "last_synced_at": "2026-10-28T03:49:26.054Z",
      "location_count": 46,
      "location_summary": "Mobile, Alabama • Glendale, Arizona • Fort Smith, Arkansas + 40 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Encinitas",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03812510"
    },
    {
      "nct_id": "NCT05028582",
      "title": "Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Scalp Psoriasis"
      ],
      "interventions": [
        {
          "name": "Roflumilast Foam 0.3%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Foam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arcutis Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 432,
      "start_date": "2021-08-24",
      "completion_date": "2022-06-03",
      "has_results": true,
      "last_update_posted_date": "2025-07-17",
      "last_synced_at": "2026-10-28T03:49:26.054Z",
      "location_count": 36,
      "location_summary": "Scottsdale, Arizona • Beverly Hills, California • Encinitas, California + 31 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05028582"
    },
    {
      "nct_id": "NCT03779659",
      "title": "Effectiveness of Synapse Transcutaneous Electronic Nerve Stimulation (TENS) During Dental Procedures Among Children",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Dental Fear",
        "Anesthesia, Local",
        "Pediatric Dentistry"
      ],
      "interventions": [
        {
          "name": "Synapse TENS device",
          "type": "DEVICE"
        },
        {
          "name": "Topical anesthetic gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Boston University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "14 Years",
        "sex": "ALL",
        "summary": "6 Years to 14 Years"
      },
      "enrollment_count": 0,
      "start_date": "2021-07",
      "completion_date": "2023-02",
      "has_results": false,
      "last_update_posted_date": "2021-06-08",
      "last_synced_at": "2026-10-28T03:49:26.054Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03779659"
    },
    {
      "nct_id": "NCT00089180",
      "title": "T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Actinic Keratosis",
        "Basal Cell Carcinoma of the Skin",
        "Recurrent Skin Cancer",
        "Squamous Cell Carcinoma of the Skin"
      ],
      "interventions": [
        {
          "name": "liposomal T4N5 lotion",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2004-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-12-04",
      "last_synced_at": "2026-10-28T03:49:26.054Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00089180"
    },
    {
      "nct_id": "NCT04285580",
      "title": "A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Open-Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Bimatoprost SR",
          "type": "DRUG"
        },
        {
          "name": "LUMIGAN",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2020-06-11",
      "completion_date": "2022-05-14",
      "has_results": true,
      "last_update_posted_date": "2023-06-08",
      "last_synced_at": "2026-10-28T03:49:26.054Z",
      "location_count": 6,
      "location_summary": "Dothan, Alabama • Newport Beach, California • Roswell, Georgia + 3 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Roswell",
          "state": "Georgia"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Cranberry Township",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04285580"
    },
    {
      "nct_id": "NCT03467789",
      "title": "Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Basal Cell Carcinoma",
        "Basal Cell Nevus Syndrome"
      ],
      "interventions": [
        {
          "name": "Dietary Vitamin D3 pre-treatment",
          "type": "DRUG"
        },
        {
          "name": "Photodynamic therapy",
          "type": "RADIATION"
        },
        {
          "name": "Serum Maintenance Vitamin D3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 37,
      "start_date": "2018-10-01",
      "completion_date": "2023-01-06",
      "has_results": false,
      "last_update_posted_date": "2024-10-17",
      "last_synced_at": "2026-10-28T03:49:26.054Z",
      "location_count": 2,
      "location_summary": "Phoenix, Arizona • Cleveland, Ohio",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03467789"
    },
    {
      "nct_id": "NCT02809118",
      "title": "Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hearing Loss, Idiopathic Sudden Sensorineural"
      ],
      "interventions": [
        {
          "name": "AM-111 0.4 mg/ml",
          "type": "DRUG"
        },
        {
          "name": "AM-111 0.8 mg/ml",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Auris Medical, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2016-06",
      "completion_date": "2018-02",
      "has_results": true,
      "last_update_posted_date": "2020-08-07",
      "last_synced_at": "2026-10-28T03:49:26.054Z",
      "location_count": 38,
      "location_summary": "Birmingham, Alabama • Escondido, California • Fresno, California + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02809118"
    },
    {
      "nct_id": "NCT03829618",
      "title": "Lidocaine Administration During Flexible Bronchoscopy and Endobronchial Ultrasound",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bronchiectasis Adult",
        "Mediastinal Lymphadenopathy",
        "Pneumonia",
        "Chest--Diseases",
        "Infiltrates",
        "Bronchopulmonary Disease",
        "Cancer, Lung"
      ],
      "interventions": [
        {
          "name": "Topical lidocaine",
          "type": "DRUG"
        },
        {
          "name": "Nebuliser solution",
          "type": "DRUG"
        },
        {
          "name": "Nebuliser Suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2019-04-01",
      "completion_date": "2020-08-31",
      "has_results": true,
      "last_update_posted_date": "2021-10-12",
      "last_synced_at": "2026-10-28T03:49:26.054Z",
      "location_count": 1,
      "location_summary": "Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03829618"
    },
    {
      "nct_id": "NCT02652780",
      "title": "Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Optic, Atrophy, Hereditary, Leber"
      ],
      "interventions": [
        {
          "name": "GS010",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sham Intravitreal Injection",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "GenSight Biologics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2016-01",
      "completion_date": "2018-12",
      "has_results": true,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-10-28T03:49:26.054Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Atlanta, Georgia • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02652780"
    }
  ]
}